Trial Profile

A Multicenter, Blinded, Randomized, Phase 2 Study of XPro1595 to Investigate the Effects of the Next Generation TNF Inhibitor (XPro1595) on Inflammation-Related Deficits in Reward Circuitry and Motivation in Depression

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Mar 2025 According to an INmune Bio media release, trial will begin enrollment soon once the NIH releases funds for the trial.
02 Aug 2024 According to an INmune Bio media release, the trial expected to initiate by 2H 2024
05 May 2022 According to an INmune Bio media release, this trial will be funded in part by a $2.9 million NIH grant, by 2H 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com